Short answer
Replimune Group, Inc. (REPL) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$57M
- +31.3% YoY · +18.1% QoQ
- EPS (diluted)
- −$0.54
- +40.0% YoY · +25.0% QoQ
Source: XBRL data from the Replimune Group, Inc. (REPL) Q3 2026 10-Q on SEC EDGAR. USD.
Replimune Group, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales before TUDRIQEV commercialization in early October 2026
- Operating margin not meaningful: operating loss $56.3M vs $84.3M YoY, net loss $57.1M vs $83.1M
- Best program RP2: R&D spending $9.4M, up $4.2M YoY; worst RP1: $8.6M, down $9.0M
- Operating cash outflow $123.4M; cash and equivalents plus short-term investments $307.8M at September 30, 2026
- Outlook: cash sufficient for greater than twelve months; continued losses, commercialization and confirmatory-trial costs expectedETwitter
Risk Factors
- New commercialization risk triggered by August 2026 FDA approval: rebuilding sales capabilities after significant reductions in force may delay TUDRIQEV launch
- Most material regulatory update: accelerated approval depends on IGNYTE-3 confirmation, with FDA withdrawal possible if clinical benefit is unverified
- Near-term market risk: TUDRIQEV remains the sole approved product, making revenue dependent on U.S. adoption in its melanoma indication
- Financial risk: $307.8 million cash at September 30, 2026, but additional financing remains necessary and may be unavailable on acceptable terms
- Manufacturing risk: approximately 63,000-square-foot Framingham facility may incur higher-than-expected costs or fail to achieve anticipated operating efficiencies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Replimune Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.